Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.
Sekisui Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years. We continue to invest in new diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. We are a leading provider of rapid tests in the U.S., and high throughput coagulation systems in Japan. We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through direct sales, our commercial distribution networks and our partners.
Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling. In January 2018 Selcia became part of Eurofins Pharma Discovery Services affording Selcia the capacity to deliver extensive and seamless solutions and services that span the whole spectrum of drug discovery.
Selcia Drug Discovery focusses on integrated small molecule drug discovery, with a strong track record of IP generation and preclinical candidate delivery for customers – 25 patents and 11 preclinical candidates generated. USPs are the medicinal chemistry of macrocycles, and a peptidyl prolyl isomerase (PPIase) screening platform.
Selcia radiolabelling specialises in 14C GMP radiolabelling, producing 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, IV microdosing, dermal penetration, regulatory and environmental fate studies.
Selcia also offers GLP NMR and mass spectrometry services to support regulatory submissions, and specialised purification capabilities from analytical (µg) to multi-100g scale.
Areas of Expertise:
• Medicinal chemistry: Tool compounds; peptides; macrocycles; natural product chemistry
• Biology: Assay development; ADME screens; PPIase profiling
• Disease expertise: Anti-infectives; inflammation; CNS; pain; metabolic; oncology & ophthalmology
• Target classes: GPCRs; ion channels; enzymes; protein-protein interactions
• 14C Custom Radiosynthesis
• GMP 14C Radiolabelled API for Clinical Trials
• GLP/GMP Analytics – GLP NMR
• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Syne qua non Ltd
Syne qua non Limited (SQN) is one of the world’s recognised specialist clinical biometrics CROs supporting global pharma, biotech, medical device and animal health partners with innovative clinical development services. SQN was previously honoured with a Queen’s Award for Enterprise in 2009, in the international trade category in recognition of our business growth and export performance. We are extremely proud to have won the 2017 Queen’s Award for Innovation for Syne-clin, our innovative EDC and Trial Management system.
Utilising standard validated library elements to build each study system, Syne-clin delivers significant time and cost savings and shortens the drug development cycle, accelerating the process of getting new medical treatments to market. Incorporating mobile, tablet and smartphone device data collection, Syne-clin allows real-time collection of patient clinical outcomes utilising electronic diary and questionnaire functionality.
Our technology and innovation project has also allowed SQN to successfully compete internationally and win clinical research projects from overseas competition thus supporting and enhancing the reputation of the UK as a centre of excellence for pharmaceutical and healthcare research. This trend continues as the rapid and ongoing development of mobile and wearable devices creates opportunities to collect patient data in ways previously not possible. Our technology incorporates these developments and allows enhanced functionality and added value, this will allow us to continue to increase market share and generate new business opportunities.
For a demo of the system come and see us at Stand 89A
Synpromics is a life science company focused on the field of synthetic biology. The Company's proprietary technology enables the design of optimized synthetic promoters that provide more effective and efficient gene regulation.
Winner of OBN Best Synthetic Biology Company Award.
SYNthesis Med Chem
SYNthesis med chem a chemistry-focussed contract research organisation that carries out custom synthesis, medicinal chemistry and integrated drug discovery projects for biotech & pharma companies and research institutes. In addition to providing chemistry services, SYNthesis also establishes shared risk collaborations with partners, the goal being to identify, develop and partner small molecule drugs.